Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "ESMO-MCBS (3)</span>]''' |- |}" to "ESMO-MCBS (3)</span>]''' |- |} -->") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"" to "<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"") |
||
| Line 24: | Line 24: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)] | ||
| − | {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | + | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" |
|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-314-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-314-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | ||
|- | |- | ||
Revision as of 15:26, 6 October 2023
| Page editor | Section editor | ||
|---|---|---|---|
 |
Teja Ganta, MD Icahn School of Medicine at Mount Sinai New York, NY, USA |
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA |
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
All lines of therapy
Belzutifan monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Jonasch et al. 2021 (MK-6482-004) | 2018-05-31 to 2019-03-29 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03401788